LIQUIDITY (Details) - USD ($) $ in Thousands				1 Months Ended		12 Months Ended
	Jun. 25, 2024	Jun. 24, 2024	Nov. 14, 2023	Jul. 31, 2024	Apr. 30, 2024	Jun. 30, 2024	Jun. 30, 2023
Net Income (Loss)						$ (68,459)	$ (51,787)
Net cash used in operating activities						(57,368)	(44,481)
Accumulated deficit						(329,444)	(260,985)
Cash and cash equivalents						70,396	16,036
Marketable debt securities						56,741	102,330
Total liabilities						11,734	7,549
Current liabilities						$ 9,606	$ 5,200
At the Market Offering
Amount agreed to sell as per open market sales agreement			$ 50,000
Underwritten Public Offering
Number of shares issued		11,250,000				13,000,000.0
Proceeds after underwriting discounts and other offering costs						$ 62,600
Proceeds From Issuance Of Common Stock, Net Of Underwriting Discounts And Commissions		$ 62,600
Underwritten Public Offering | Pre Funded Warrants 2024
Warrants issued						3,750,000
Private Placement
Number of shares issued	1,500,000
Private Placement | Subsequent Event
Number of shares issued				1,500,000
Proceeds From Issuance Of Common Stock, Net Of Underwriting Discounts And Commissions				$ 6,000
XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 (ersodetug) | Xoma License Agreement
Milestone closing payment					$ 5,000
XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 (ersodetug) | Xoma License Agreement | Scenario, Upon Dosing Of The Last Patient
Milestone closing payment						$ 5,000